ABSTRACT
The Omicron (B.1.1.529), fifth variant of concern (VOC) of SARS-CoV-2, initially identified following a steep increase in COVID-19 cases in Southern Africa in November 2021. It is a highly-mutated variant and is more contagious as compared with the Delta variant, however less deadly. Due to its high transmission rate, it spreads dramatically, and causing huge surges worldwide. It causes "mild infection”, with hospitalisations less likely to occur. However, this variant is known to show resistance to neutralizing antibodies (nAbs) generated through vaccination and/or prior infection as well as to monoclonal antibodies (mAbs) used to treat COVID-19 patients. In many countries, booster doses of vaccines have been recommended to increase the protective levels of antibodies in vaccinated individuals. Along with the implementation of appropriate prevention and control strategy measures, current efforts are also focussed on the development of better vaccines and mAbs to counter this variant. This review highlights the global health concerns and challenges posed by the Omicron variant and present an update on its sub-lineages. © 2023 Wiley-VCH GmbH.
ABSTRACT
A novel Schiff base (SB) ligand, abbreviated as HDMPM, resulted from the condensation of 2-amino-4 -phenyl-5-methyl thiazole and 4-(diethylamino)salicyaldehyde, and its metal complexes with [Co(II), Cu(II), Ni(II), and Zn(II)] ions in high yield were formed. The physico-chemical techniques such as elemental analysis, molar conductance, IR, 1 H and 13 C NMR, mass spectroscopy, and electronic absorption studies were utilized to characterize the synthesized compounds. The studied compounds were examined for their possible anticancer activity against a number of human cancerous cell lines, including A549 lung carcinoma, HepG2 liver cancer, HCT116 colorectal cancer, and MCF-7 breast cancer cell lines, with dox-orubicin serving as the standard. The study revealed that Zn(II) complex showed significant activity to inhibit growth of HepG2, MCF7, A549, and HCT116 cell lines by a factor of 88, 70, 75, and 70, respec-tively, when compared to untreated. In addition, the reported compounds were optimized by employing Gaussian16 program package with B3LYP functional incorporating dispersion with two different basis sets (LanL2DZ and 6-31G(d,p)). Moreover, Autodock Vina software was used to assess the biological effective-ness of the studied compounds against SARS-CoV-2 Omicron variant (PDB ID: 7T9K).(c) 2022 Elsevier B.V. All rights reserved.
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (S ARS-CoV-2) emerging variants particularly those of concern contain numerous mutations that influence the behavior and transmissibility of the virus and could adversely affect the efficacies of existing coronavirus disease 2019 (COVID-19) vaccines and immunotherapies. The emerging SARS-CoV-2 variants have resulted in different waves of the pandemic within the ongoing COVID-19 pandemic. On 26 November 2021 World Health Organization designated omicron (B.1.1.529) as the fifth variant of concern which was first reported from South Africa on November 24, 2021, and thereafter rapidly spread across the globe owing to its very high transmission rates along with impeding efficacies of existing vaccines and immunotherapies. Omicron contains more than 50 mutations with many mutations (26-32) in spike protein that might be associated with high transmissibility. Natural compounds particularly phytochemicals have been used since ancient times for the treatment of different diseases, and owing to their potent anti-viral properties have also been explored recently against COVID-19. In the present study, molecular docking of nine phytochemicals (Oleocanthal, Tangeritin, Coumarin, Malvidin, Glycitein, Piceatannol, Pinosylnin, Daidzein, and Naringenin) with omicron spike protein (7QNW (electron microscopy, resolution 2.40 Å) was done. The docking study revealed that selected ligands interact with the receptor with binding energy in the range of-6.2 to-7.0 kcal/mol. Pinosylnin showed the highest binding energy of-7.0 kcal/mol which may be used as potential ligands against omicron spike protein. Based on the docking studies, it was suggested that these phytochemicals are potential molecules to be tested against omicron SARS-CoV-2 and can be used to develop effective antiviral drugs. © 2022, Editorial board of Journal of Experimental Biology and Agricultural Sciences. All rights reserved.
ABSTRACT
COVID-19 has been categorized as a pandemic in early 2020 and is known to cause by Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV2). Numerous investigators and people in the scientific community are trying to find a superlative way to avert and cure the ailment by using phytochemicals. Abundant studies have revealed that flavonoids can be very operative in averting virus-mediated infection. The purpose of this study was to accomplish molecular docking studies among plant-derived flavonoids (Apigenin, Kaempferol, and Quercetin) and spike receptor (PDB ID: 2AJF) protein of coronavirus. Pyrx virtual screening tool and biovia discovery studio visualizer were utilized in the current molecular docking investigations. Outcomes of docking studies exposed that selected phytochemicals have interacted with targeted spike receptor protein with binding energies in the range of -6.3 to -7.3 kcal. In conclusion among the various selected ligands, quercetin may be a better inhibitor for the deactivation of SARS-Coronavirus.